Tandem Diabetes Care Stock Operating Margin

TNDM Stock

USD 34.97 3.24 10.21%

Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.

		Last Reported	Projected for Next Year
	Operating Profit Margin	(0.31)	(0.33)

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tandem Diabetes Care Company Operating Margin Analysis

Tandem Diabetes' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Current Tandem Diabetes Operating Margin

(0.18) %

Most of Tandem Diabetes' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tandem Diabetes Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Tandem Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Tandem Diabetes is extremely important. It helps to project a fair market value of Tandem Stock properly, considering its historical fundamentals such as Operating Margin. Since Tandem Diabetes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tandem Diabetes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tandem Diabetes' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Intangible Assets	Long Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.88	0.9	-0.86	0.82	0.99	0.97	0.96	1.0	-0.27	0.78	0.97	0.78	0.56	0.85	0.98	0.93	0.9	0.58	0.6	0.97	0.96	0.97
Total Stockholder Equity	0.88		0.63	-0.76	0.65	0.88	0.9	0.72	0.9	-0.34	0.91	0.77	0.45	0.61	0.89	0.83	0.81	0.9	0.56	0.63	0.92	0.92	0.74
Net Debt	0.9	0.63		-0.79	0.81	0.89	0.87	0.97	0.88	-0.04	0.54	0.93	0.89	0.45	0.69	0.89	0.84	0.76	0.56	0.53	0.84	0.84	0.95
Retained Earnings	-0.86	-0.76	-0.79		-0.9	-0.89	-0.81	-0.81	-0.85	0.03	-0.85	-0.92	-0.78	-0.24	-0.87	-0.84	-0.94	-0.89	-0.78	-0.82	-0.78	-0.78	-0.83
Accounts Payable	0.82	0.65	0.81	-0.9		0.84	0.73	0.83	0.8	0.01	0.72	0.87	0.8	0.11	0.77	0.77	0.87	0.78	0.65	0.67	0.72	0.72	0.81
Net Receivables	0.99	0.88	0.89	-0.89	0.84		0.98	0.94	0.99	-0.25	0.82	0.96	0.76	0.54	0.9	0.97	0.96	0.93	0.66	0.67	0.97	0.97	0.95
Short Term Investments	0.97	0.9	0.87	-0.81	0.73	0.98		0.92	0.99	-0.31	0.78	0.91	0.69	0.67	0.86	0.96	0.9	0.89	0.56	0.59	0.98	0.98	0.93
Total Liab	0.96	0.72	0.97	-0.81	0.83	0.94	0.92		0.94	-0.19	0.62	0.97	0.88	0.49	0.76	0.95	0.89	0.83	0.55	0.54	0.91	0.9	0.98
Total Current Assets	1.0	0.9	0.88	-0.85	0.8	0.99	0.99	0.94		-0.29	0.8	0.95	0.74	0.6	0.87	0.97	0.92	0.91	0.58	0.6	0.98	0.98	0.95
Short Term Debt	-0.27	-0.34	-0.04	0.03	0.01	-0.25	-0.31	-0.19	-0.29		-0.25	-0.15	-0.1	-0.33	-0.28	-0.41	-0.25	-0.28	0.08	0.23	-0.32	-0.32	-0.25
Common Stock	0.78	0.91	0.54	-0.85	0.72	0.82	0.78	0.62	0.8	-0.25		0.74	0.47	0.35	0.92	0.76	0.84	0.9	0.59	0.76	0.79	0.79	0.66
Property Plant Equipment	0.97	0.77	0.93	-0.92	0.87	0.96	0.91	0.97	0.95	-0.15	0.74		0.88	0.42	0.81	0.95	0.93	0.87	0.63	0.63	0.89	0.88	0.98
Current Deferred Revenue	0.78	0.45	0.89	-0.78	0.8	0.76	0.69	0.88	0.74	-0.1	0.47	0.88		0.13	0.56	0.81	0.79	0.64	0.47	0.42	0.64	0.63	0.89
Intangible Assets	0.56	0.61	0.45	-0.24	0.11	0.54	0.67	0.49	0.6	-0.33	0.35	0.42	0.13		0.39	0.55	0.35	0.46	0.14	0.17	0.69	0.68	0.49
Long Term Debt	0.85	0.89	0.69	-0.87	0.77	0.9	0.86	0.76	0.87	-0.28	0.92	0.81	0.56	0.39		0.83	0.92	0.97	0.73	0.83	0.89	0.89	0.76
Net Tangible Assets	0.98	0.83	0.89	-0.84	0.77	0.97	0.96	0.95	0.97	-0.41	0.76	0.95	0.81	0.55	0.83		0.93	0.89	0.54	0.53	0.94	0.94	0.97
Long Term Debt Total	0.93	0.81	0.84	-0.94	0.87	0.96	0.9	0.89	0.92	-0.25	0.84	0.93	0.79	0.35	0.92	0.93		0.92	0.7	0.75	0.88	0.88	0.91
Capital Surpluse	0.9	0.9	0.76	-0.89	0.78	0.93	0.89	0.83	0.91	-0.28	0.9	0.87	0.64	0.46	0.97	0.89	0.92		0.73	0.78	0.92	0.92	0.82
Deferred Long Term Liab	0.58	0.56	0.56	-0.78	0.65	0.66	0.56	0.55	0.58	0.08	0.59	0.63	0.47	0.14	0.73	0.54	0.7	0.73		0.8	0.58	0.58	0.54
Short Long Term Debt	0.6	0.63	0.53	-0.82	0.67	0.67	0.59	0.54	0.6	0.23	0.76	0.63	0.42	0.17	0.83	0.53	0.75	0.78	0.8		0.61	0.62	0.51
Net Invested Capital	0.97	0.92	0.84	-0.78	0.72	0.97	0.98	0.91	0.98	-0.32	0.79	0.89	0.64	0.69	0.89	0.94	0.88	0.92	0.58	0.61		1.0	0.9
Net Working Capital	0.96	0.92	0.84	-0.78	0.72	0.97	0.98	0.9	0.98	-0.32	0.79	0.88	0.63	0.68	0.89	0.94	0.88	0.92	0.58	0.62	1.0		0.89
Capital Stock	0.97	0.74	0.95	-0.83	0.81	0.95	0.93	0.98	0.95	-0.25	0.66	0.98	0.89	0.49	0.76	0.97	0.91	0.82	0.54	0.51	0.9	0.89

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict Tandem Diabetes

Operating Profit Margin Over Time

Tandem Pretax Profit Margin

Pretax Profit Margin

(0.31)

At this time, Tandem Diabetes' Pretax Profit Margin is very stable compared to the past year.

Based on the recorded statements, Tandem Diabetes Care has an Operating Margin of -0.1781%. This is 99.49% lower than that of the Health Care Equipment & Supplies sector and 99.55% lower than that of the Health Care industry. The operating margin for all United States stocks is 96.77% lower than that of the firm.

Tandem Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tandem Diabetes' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics of similar companies.

Tandem Diabetes is currently under evaluation in operating margin category among related companies.

Tandem Fundamentals

	Return On Equity	-0.59
	Return On Asset	-0.0963
	Profit Margin	(0.30) %
	Operating Margin	(0.18) %
	Current Valuation	2.03 B
	Shares Outstanding	64.56 M
	Shares Owned By Insiders	0.60 %
	Shares Owned By Institutions	99.40 %
	Number Of Shares Shorted	9.31 M
	Price To Earning	494.25 X
	Price To Book	6.90 X
	Price To Sales	2.89 X
	Revenue	747.72 M
	Gross Profit	412.99 M
	EBITDA	(118.22 M)
	Net Income	(222.61 M)
	Cash And Equivalents	608.73 M
	Cash Per Share	9.47 X
	Total Debt	415.67 M
	Debt To Equity	1.00 %
	Current Ratio	4.80 X
	Book Value Per Share	4.78 X
	Cash Flow From Operations	(31.81 M)
	Short Ratio	4.00 X
	Earnings Per Share	(3.43) X
	Target Price	35.93
	Number Of Employees	2.4 K
	Beta	1.13
	Market Capitalization	2.05 B
	Total Asset	952.66 M
	Retained Earnings	(951.8 M)
	Working Capital	552.73 M
	Current Asset	106.98 M
	Current Liabilities	26.52 M
	Net Asset	952.66 M

About Tandem Diabetes Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Tandem Diabetes Investors Sentiment

The influence of Tandem Diabetes' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Tandem. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Tandem Diabetes' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tandem Diabetes' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Tandem Diabetes' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Tandem Diabetes.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tandem Diabetes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tandem Diabetes' short interest history, or implied volatility extrapolated from Tandem Diabetes options trading.

Currently Active Assets on Macroaxis

GOOG	Alphabet Inc Class C
DD	Dupont De Nemours
C	Citigroup
CRM	Salesforce
GM	General Motors

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:

How To Invest In Tandem

Details

Is Tandem Stock a good investment?

Details

What is Tandem Diabetes' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Tandem Diabetes Piotroski F Score and Tandem Diabetes Altman Z Score analysis.

Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.

	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Transaction History View history of all your transactions and understand their impact on performance
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Global Correlations Find global opportunities by holding instruments from different markets
	CEOs Directory Screen CEOs from public companies around the world
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.37)

Earnings Share

(3.43)

Revenue Per Share

11.509

Quarterly Revenue Growth

(0.11)

Return On Assets

(0.1)

The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tandem Diabetes Care Stock Operating Margin

Tandem Diabetes Care Company Operating Margin Analysis

Operating Margin

Operating Income

Revenue

100

Current Tandem Diabetes Operating Margin

Tandem Operating Margin Driver Correlations

Tandem Pretax Profit Margin

Pretax Profit Margin

(0.31)

Tandem Operating Margin Peer Comparison

Tandem Fundamentals

About Tandem Diabetes Fundamental Analysis

Tandem Diabetes Investors Sentiment

Currently Active Assets on Macroaxis

Complementary Tools for Tandem Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY